AU2003249533A8 - Neoplasm specific antibodies and uses thereof - Google Patents
Neoplasm specific antibodies and uses thereofInfo
- Publication number
- AU2003249533A8 AU2003249533A8 AU2003249533A AU2003249533A AU2003249533A8 AU 2003249533 A8 AU2003249533 A8 AU 2003249533A8 AU 2003249533 A AU2003249533 A AU 2003249533A AU 2003249533 A AU2003249533 A AU 2003249533A AU 2003249533 A8 AU2003249533 A8 AU 2003249533A8
- Authority
- AU
- Australia
- Prior art keywords
- specific antibodies
- neoplasm specific
- neoplasm
- antibodies
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 208000035269 cancer or benign tumor Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2002129907 DE10229907A1 (en) | 2002-07-04 | 2002-07-04 | New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans |
DE10229907.2 | 2002-07-04 | ||
DE2002129906 DE10229906A1 (en) | 2002-07-04 | 2002-07-04 | New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans |
DE10229906.4 | 2002-07-04 | ||
DE10230516.1 | 2002-07-06 | ||
DE2002130516 DE10230516A1 (en) | 2002-07-06 | 2002-07-06 | New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans |
PCT/IB2003/003487 WO2004005351A2 (en) | 2002-07-04 | 2003-07-02 | Neoplasm specific antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003249533A8 true AU2003249533A8 (en) | 2004-01-23 |
AU2003249533A1 AU2003249533A1 (en) | 2004-01-23 |
Family
ID=30773222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003249533A Abandoned AU2003249533A1 (en) | 2002-07-04 | 2003-07-02 | Neoplasm specific antibodies and uses thereof |
Country Status (5)
Country | Link |
---|---|
US (3) | US7772372B2 (en) |
EP (2) | EP2322559A3 (en) |
AU (1) | AU2003249533A1 (en) |
CA (1) | CA2491669A1 (en) |
WO (1) | WO2004005351A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE490271T1 (en) | 2001-07-24 | 2010-12-15 | Debiovision Inc | RECEPTOR, ITS USE AND MOUSE ANTIBODIES |
WO2004005351A2 (en) | 2002-07-04 | 2004-01-15 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
DE10311248A1 (en) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Human monoclonal antibody |
EP1531162A1 (en) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
DE10353175A1 (en) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Human monoclonal antibody with fatliquoring effect |
WO2008058379A1 (en) * | 2006-11-13 | 2008-05-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
AU2008340011A1 (en) * | 2007-12-21 | 2009-07-02 | Patrys Limited | PM-2 antibodies and methods for treating metastasis |
US11046764B2 (en) | 2017-01-03 | 2021-06-29 | Trellis Bioscience, Llc | Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5374548A (en) * | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
US5001225A (en) * | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
DE3722647A1 (en) | 1987-07-09 | 1989-01-19 | Gerhard Ohlenschlaeger | GALENIC USE OF A TRIPEPTID AS A MEDICINAL PRODUCT |
DE4107154A1 (en) | 1990-10-11 | 1992-04-16 | Boehringer Mannheim Gmbh | MONOCLONAL ANTICOERPER AGAINST MELANOMA |
AU662311B2 (en) | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
GB9105292D0 (en) | 1991-03-13 | 1991-04-24 | Sandoz Ltd | Improvements in or relating to organic compounds |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US5367060A (en) | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
US5639863A (en) * | 1994-06-21 | 1997-06-17 | Dan; Michael D. | Human monoclonal antibodies specific to cell cycle independent glioma surface antigen |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
US6140470A (en) | 1995-06-30 | 2000-10-31 | Yale University | Human monoclonal anti-tumor antibodies |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
EP1695986B1 (en) | 1996-10-18 | 2016-12-14 | Genentech, Inc. | Anti-erb B2 antibodies |
EP0927757A1 (en) | 1997-12-03 | 1999-07-07 | Leadd B.V. | Methods and means for inducing apoptosis by interfering with Bip-like proteins |
EP1068312A2 (en) | 1998-04-09 | 2001-01-17 | Genset | 5' ests and encoded human proteins |
ATE391136T1 (en) | 1998-06-18 | 2008-04-15 | Imed Ab | FAS PEPTIDES AND ANTIBODIES FOR MODULATING APOPTOSIS |
GB9822115D0 (en) * | 1998-10-09 | 1998-12-02 | King S College London | Treatment of inflammatory disease |
WO2000037489A2 (en) | 1998-12-22 | 2000-06-29 | Heinz Peter Vollmers | Fragment of the gylcoprotein cd55/daf for producing highly effective anti-tumour medicaments and method for using the same |
US7049132B1 (en) * | 1999-06-28 | 2006-05-23 | University Of Southern California | Stress-responsive induction of a therapeutic agent and methods of use |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
US6794494B1 (en) * | 2003-04-14 | 2004-09-21 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US6677442B1 (en) * | 1999-10-29 | 2004-01-13 | University Of Kentucky Research Foundation | Nucleic acid encoding human REV1 protein |
MXPA02008144A (en) | 2000-02-23 | 2002-11-29 | Amgen Inc | Antagonistic selective binding agents of osteoprotegerin binding protein. |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
KR101287395B1 (en) | 2000-06-16 | 2014-11-04 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Antibodies that immunospecifically bind to BLyS |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
WO2002036142A2 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
EP1390741B1 (en) | 2001-04-17 | 2012-10-31 | Abmaxis, Inc. | Structure-based construction of human antibody library |
ATE490271T1 (en) | 2001-07-24 | 2010-12-15 | Debiovision Inc | RECEPTOR, ITS USE AND MOUSE ANTIBODIES |
WO2003048321A2 (en) * | 2001-12-03 | 2003-06-12 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
DE10210427A1 (en) | 2002-03-09 | 2003-10-09 | Hans Konrad Mueller-Hermelink | Human monoclonal antibody |
DE10230516A1 (en) | 2002-07-06 | 2004-01-15 | Müller-Hermelink, Hans Konrad, Prof. Dr. | New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans |
DE10229907A1 (en) | 2002-07-04 | 2004-01-22 | Müller-Hermelink, Hans Konrad, Prof. Dr. | New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans |
DE10229906A1 (en) | 2002-07-04 | 2004-01-22 | Müller-Hermelink, Hans Konrad, Prof. Dr. | New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans |
WO2004005351A2 (en) | 2002-07-04 | 2004-01-15 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
CA2496938A1 (en) | 2002-08-30 | 2004-03-11 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
DE10311248A1 (en) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Human monoclonal antibody |
US20050123571A1 (en) * | 2003-06-06 | 2005-06-09 | Rossini Aldo A. | Modulation of apoptosis |
EP1678497B1 (en) | 2003-10-27 | 2011-05-11 | University Of Southern California | Methods and compositions for modulating apoptosis |
NZ577824A (en) | 2003-11-12 | 2010-10-29 | Patrys Ltd | Methods of identifying neoplasm-specific antibodies and uses thereof |
EP1531162A1 (en) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
WO2005065418A2 (en) | 2003-12-31 | 2005-07-21 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy |
GB0404936D0 (en) | 2004-03-04 | 2004-04-07 | Univ London | Screen |
DE102004015179A1 (en) * | 2004-03-25 | 2005-10-13 | Oncomab Gmbh | Antigen of the PM-2 antibody and its use |
-
2003
- 2003-07-02 WO PCT/IB2003/003487 patent/WO2004005351A2/en active Search and Examination
- 2003-07-02 CA CA002491669A patent/CA2491669A1/en not_active Abandoned
- 2003-07-02 AU AU2003249533A patent/AU2003249533A1/en not_active Abandoned
- 2003-07-02 EP EP10182205A patent/EP2322559A3/en not_active Withdrawn
- 2003-07-02 US US10/520,224 patent/US7772372B2/en not_active Expired - Fee Related
- 2003-07-02 EP EP03762849A patent/EP1521776A2/en not_active Withdrawn
-
2007
- 2007-08-14 US US11/838,603 patent/US7741444B2/en not_active Expired - Fee Related
-
2010
- 2010-06-07 US US12/795,516 patent/US20100317826A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1521776A2 (en) | 2005-04-13 |
WO2004005351A3 (en) | 2004-07-01 |
US20060074229A1 (en) | 2006-04-06 |
WO2004005351A2 (en) | 2004-01-15 |
EP2322559A3 (en) | 2011-08-03 |
EP2322559A2 (en) | 2011-05-18 |
US7772372B2 (en) | 2010-08-10 |
US20080020457A1 (en) | 2008-01-24 |
CA2491669A1 (en) | 2004-01-15 |
US7741444B2 (en) | 2010-06-22 |
US20100317826A1 (en) | 2010-12-16 |
AU2003249533A1 (en) | 2004-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL225633A0 (en) | Anti-alpha-v-beta - 6 antibodies and uses thereof | |
EP1551447A4 (en) | Anti-addl antibodies and uses thereof | |
HK1248731A1 (en) | Immunoglobulin variants and uses thereof | |
EP1551877A4 (en) | Taci antibodies and uses thereof | |
AU2003299778A8 (en) | Antibodies against gpr64 and uses thereof | |
IL172871A0 (en) | Rg1 antibodies and uses thereof | |
SI2368907T1 (en) | Anti-Abeta antibodies and their use | |
EP1494693A4 (en) | Cripto-specific antibodies | |
EP1539941A4 (en) | Adzymes and uses thereof | |
EP1699485A4 (en) | Anti-hydroxylase antibodies and uses thereof | |
IL172510A0 (en) | Antibodies and uses thereof | |
AU2003219093A8 (en) | Anti-hpv-16 e7 antibodies and their use | |
IL166063A0 (en) | Antibodies and uses thereof | |
EP1589033A4 (en) | Antibody and use thereof | |
AU2003283963A8 (en) | Mage-c2 antigenic peptides and uses thereof | |
AU2003249533A8 (en) | Neoplasm specific antibodies and uses thereof | |
AU2003231827A8 (en) | Pseudo-tissues and uses thereof | |
AU2003298739A8 (en) | Intermedin and its uses | |
EP1541588A4 (en) | Single chain antibody and utilization thereof | |
EP1627888A4 (en) | Antibody and use thereof | |
GB0227080D0 (en) | Antibodies and uses thereof | |
EP1557430A4 (en) | Antibody and utilization of the same | |
AU2003216442A8 (en) | Enkurin and uses thereof | |
AU2003270518A8 (en) | Therapeutic anti-bgp(c-cam1) antibodies and uses thereof | |
AU2003263751A8 (en) | Novel proteins and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |